annb0t
Top 20
The latest analyst coverage could presage a bad day for Clinuvel Pharmaceuticals Limited (ASX:CUV), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.
Following the downgrade, the most recent consensus for Clinuvel Pharmaceuticals from i...
>>> Read more: Analysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS Numbers
Following the downgrade, the most recent consensus for Clinuvel Pharmaceuticals from i...
>>> Read more: Analysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS Numbers